glp 1 agonist and alcohol use disorder Semaglutide for weight loss was linked to a sharp drop in in this case report GLP1 receptor agonists are supported
Description
Food and Drug Administration , 2022, Amisi, C
Cell Rep Med 4 Davies M, et al (2017) Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial

A multivariable sensitivity Cox model adjusting for these four covariates could not be performed because the original TriNetX dataset is no longer re-accessible

doi: 10.1530/ec-21-0130 [DOI] [PMC free article] [PubMed] [Google Scholar] 29
